A guide to Multiple System Atrophy for: Speech and Language
... to premature death. Currently, there is no known cause or cure. MSA causes degeneration or atrophy of nerve cells in several (or multiple) areas of the brain which results in problems with movement, balance and autonomic functions of the body such as swallowing, bowel, bladder and blood pressure con ...
... to premature death. Currently, there is no known cause or cure. MSA causes degeneration or atrophy of nerve cells in several (or multiple) areas of the brain which results in problems with movement, balance and autonomic functions of the body such as swallowing, bowel, bladder and blood pressure con ...
The Serotonin Syndrome, Triptans, and the Potential for Drug–Drug
... addition of a triptan to SSRIs/SNRIs or with triptan monotherapy. The currently available evidence does not support limiting the use of triptans with SSRIs or SNRIs, or the use of triptan monotherapy, due to concerns for serotonin syndrome (Level U).”11 Because of the high comorbidity of depression, ...
... addition of a triptan to SSRIs/SNRIs or with triptan monotherapy. The currently available evidence does not support limiting the use of triptans with SSRIs or SNRIs, or the use of triptan monotherapy, due to concerns for serotonin syndrome (Level U).”11 Because of the high comorbidity of depression, ...
Tumour Necrosis Factor-α (TNF-α) antagonists and Tuberculosis
... There is concern that new groups of drugs called TNF-α antagonists, which are being used effectively to modify the immune system response in the treatment of a number of immune-mediated diseases, may be associated with a risk of developing TB infection and clinically active TB disease. This briefing ...
... There is concern that new groups of drugs called TNF-α antagonists, which are being used effectively to modify the immune system response in the treatment of a number of immune-mediated diseases, may be associated with a risk of developing TB infection and clinically active TB disease. This briefing ...
- Respiratory Medicine
... of 0–3 (0 ¼ no symptoms; 3 ¼ severe symptoms preventing normal daily activities). Sleep disturbance caused by asthma was assessed before the morning dose of medication using a scale of 0–3 (0 ¼ slept through the night; 3 ¼ asthma symptoms causing wakefulness most of the night). Pulmonary function (f ...
... of 0–3 (0 ¼ no symptoms; 3 ¼ severe symptoms preventing normal daily activities). Sleep disturbance caused by asthma was assessed before the morning dose of medication using a scale of 0–3 (0 ¼ slept through the night; 3 ¼ asthma symptoms causing wakefulness most of the night). Pulmonary function (f ...
Hyperthyroidism and Thyrotoxicosis
... and irregular thyroid. One lobe can be involved first followed by the other. Thyroid hormone levels are elevated, TSH is suppressed, RAIU is close to zero, sedimentation rate is high, blood count is normal, and serum thyroglobulin level is elevated [14]. Condition is followed by a transient hypothyr ...
... and irregular thyroid. One lobe can be involved first followed by the other. Thyroid hormone levels are elevated, TSH is suppressed, RAIU is close to zero, sedimentation rate is high, blood count is normal, and serum thyroglobulin level is elevated [14]. Condition is followed by a transient hypothyr ...
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing
... The use of antiplatelet therapies continues to increase as a result of accumulation of evidence of benefits in both primary and secondary treatment strategies for cardiovascular disease (1, 2). These antiplatelet agents, however, have recognizable risks—in particular, gastrointestinal (GI) complicat ...
... The use of antiplatelet therapies continues to increase as a result of accumulation of evidence of benefits in both primary and secondary treatment strategies for cardiovascular disease (1, 2). These antiplatelet agents, however, have recognizable risks—in particular, gastrointestinal (GI) complicat ...
Treating Chronic Lymphocytic Leukemia (CLL): Evaluating and
... lymphocytes. What we don’t see here would be a normal lymphocyte to compare these to, but these lymphocytes, the blue part is a little bit more open, less dense or dark than we would see in a normal lymphocyte. So someone looking at the blood smear would recognize these as being abnormal. Slide 8. S ...
... lymphocytes. What we don’t see here would be a normal lymphocyte to compare these to, but these lymphocytes, the blue part is a little bit more open, less dense or dark than we would see in a normal lymphocyte. So someone looking at the blood smear would recognize these as being abnormal. Slide 8. S ...
Running Head: LITERATURE REVIEW Epiglottitis Tanjia Hynes
... comorbidity of diabetes mellitus and immunosuppressant increases the patients relative risk for needing airway intervention as well (Sakar et al., 2009; Kim et al., 2009; Riffat et al., 2011). ...
... comorbidity of diabetes mellitus and immunosuppressant increases the patients relative risk for needing airway intervention as well (Sakar et al., 2009; Kim et al., 2009; Riffat et al., 2011). ...
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma
... Formoterol, a rapid- and long-acting bronchodilator, can be used as a reliever as well as for maintenance therapy [5]. Budesonide/formoterol has also been assessed as reliever therapy in patients using this combination as maintenance therapy. This approach utilises a lower regular maintenance dose o ...
... Formoterol, a rapid- and long-acting bronchodilator, can be used as a reliever as well as for maintenance therapy [5]. Budesonide/formoterol has also been assessed as reliever therapy in patients using this combination as maintenance therapy. This approach utilises a lower regular maintenance dose o ...
Chronic obstructive pulmonary disease in over 16s: diagnosis
... COPD is now the preferred term for the conditions in patients with airflow obstruction who were previously diagnosed as having chronic bronchitis or emphysema. There is no single diagnostic test for COPD. Making a diagnosis relies on clinical judgement based on a combination of history, physical exa ...
... COPD is now the preferred term for the conditions in patients with airflow obstruction who were previously diagnosed as having chronic bronchitis or emphysema. There is no single diagnostic test for COPD. Making a diagnosis relies on clinical judgement based on a combination of history, physical exa ...
IDIOPATHIC THROMBOCYTOPENIC PURPURA AND
... dental surgical procedures. The cause of the platelet reduction is idiopathic; an autoimmune reaction in which the antibodies destroy the platelets appears to participate in the process. A variety of situations can occur, leading to mild to severe thrombocytopenia. One frequent aspect is the instabi ...
... dental surgical procedures. The cause of the platelet reduction is idiopathic; an autoimmune reaction in which the antibodies destroy the platelets appears to participate in the process. A variety of situations can occur, leading to mild to severe thrombocytopenia. One frequent aspect is the instabi ...
Mitochondria and Epilepsy
... Dysfunction of the mitochondrial respiratory chain associated with epilepsy Mitochondrial oxidative phosphorylation provides the major source of ATP in neurons. It consists of five multienzyme complexes located in the mitochondrial inner membrane (Figure). The complexes I to IV are oxidoreductases w ...
... Dysfunction of the mitochondrial respiratory chain associated with epilepsy Mitochondrial oxidative phosphorylation provides the major source of ATP in neurons. It consists of five multienzyme complexes located in the mitochondrial inner membrane (Figure). The complexes I to IV are oxidoreductases w ...
Raynaud`s phenomenon
... Prostaglandins are potent vasodilating agents that also inhibit platelet aggregation, decrease leukocyte margination, and exert fibrinolytic effects [2,3]. Ilomedin, a synthetic analog of prostaglandin I2, has been evaluated in Raynaud’s phenomenon secondary to connective tissue disease [32e36]. The ...
... Prostaglandins are potent vasodilating agents that also inhibit platelet aggregation, decrease leukocyte margination, and exert fibrinolytic effects [2,3]. Ilomedin, a synthetic analog of prostaglandin I2, has been evaluated in Raynaud’s phenomenon secondary to connective tissue disease [32e36]. The ...
Document
... bation rate, estimated from the number of exacerbations per pa- and linking of this to the immunological measures, we ranked the tient-years, was 1.25 during baseline, 1.38 during treatment, changes in the five disease activity parameters (EDSS, Scripps NRS, contrast-enhancing MRI lesions, BWMLL and ...
... bation rate, estimated from the number of exacerbations per pa- and linking of this to the immunological measures, we ranked the tient-years, was 1.25 during baseline, 1.38 during treatment, changes in the five disease activity parameters (EDSS, Scripps NRS, contrast-enhancing MRI lesions, BWMLL and ...
Anaphylaxis: the acute episode and beyond - pedia
... Figure 2 outlines a systematic approach to the basic initial management of anaphylaxis that emphasises the primary role of adrenaline.1 11 In healthcare settings, it is important to prepare for this medical emergency by using an anaphy‑ laxis assessment and management protocol based on cur‑ rent na ...
... Figure 2 outlines a systematic approach to the basic initial management of anaphylaxis that emphasises the primary role of adrenaline.1 11 In healthcare settings, it is important to prepare for this medical emergency by using an anaphy‑ laxis assessment and management protocol based on cur‑ rent na ...
a therapy guide in English
... ALIMTA® (pemetrexed for injection) in combination with cisplatin Most patients taking ALIMTA plus cisplatin will have side effects. For the purpose of this booklet, we will discuss some of the most common and/or most serious side effects that may happen if you take ALIMTA plus cisplatin for the firs ...
... ALIMTA® (pemetrexed for injection) in combination with cisplatin Most patients taking ALIMTA plus cisplatin will have side effects. For the purpose of this booklet, we will discuss some of the most common and/or most serious side effects that may happen if you take ALIMTA plus cisplatin for the firs ...
Problem. You are called by the nurse to evaluate a 65-year
... vertebrobasilar circulation often causes vertigo. Other signs of brain stem involvement such as diplopia, dysarthria, dysphagia, weakness, or numbness usually accompany vertigo due to brain stem ischemia. Cerebellar ischemia typically presents with vertigo and cerebellar signs; however, it may prese ...
... vertebrobasilar circulation often causes vertigo. Other signs of brain stem involvement such as diplopia, dysarthria, dysphagia, weakness, or numbness usually accompany vertigo due to brain stem ischemia. Cerebellar ischemia typically presents with vertigo and cerebellar signs; however, it may prese ...
Clinical Practice Guideline (Update)
... Sinusitis, also rhinosinusitis, affects about 1 in 8 adults annually and generally occurs when viruses or bacteria infect the sinuses (often during a cold) and begin to multiply. Part of the body’s reaction to the infection causes the sinus lining to swell, blocking the channels that drain the sinus ...
... Sinusitis, also rhinosinusitis, affects about 1 in 8 adults annually and generally occurs when viruses or bacteria infect the sinuses (often during a cold) and begin to multiply. Part of the body’s reaction to the infection causes the sinus lining to swell, blocking the channels that drain the sinus ...
Tips on how to prepare and respond PAGE 30
... The effects of budesonide inhalation suspension on the hypothalamic-pituitaryadrenal (HPA) axis were studied in three, 12-week, double-blind, placebocontrolled studies in 293 pediatric patients, 6 months to 8 years of age, with persistent asthma. For most patients, the ability to increase cortisol p ...
... The effects of budesonide inhalation suspension on the hypothalamic-pituitaryadrenal (HPA) axis were studied in three, 12-week, double-blind, placebocontrolled studies in 293 pediatric patients, 6 months to 8 years of age, with persistent asthma. For most patients, the ability to increase cortisol p ...
NHS Highland - Community Pharmacy Scotland
... Beclometasone should only be prescribed for anyone aged 18 years of age or over. Advise patients that beclometasone nasal spray usually takes several days to take effect and instant relief should not be expected it should however be used every day for maximum benefit. Advise once symptoms cont ...
... Beclometasone should only be prescribed for anyone aged 18 years of age or over. Advise patients that beclometasone nasal spray usually takes several days to take effect and instant relief should not be expected it should however be used every day for maximum benefit. Advise once symptoms cont ...
Consultation Protocol - Word 240 KB
... the Minister for Health and Ageing (the Minister) to strengthen the role of evidence in health financing decisions in Australia. MSAC advises the Minister on the evidence relating to the safety, effectiveness, and cost-effectiveness of new and existing medical technologies and procedures and under w ...
... the Minister for Health and Ageing (the Minister) to strengthen the role of evidence in health financing decisions in Australia. MSAC advises the Minister on the evidence relating to the safety, effectiveness, and cost-effectiveness of new and existing medical technologies and procedures and under w ...
What is Psoriasis? - Persatuan Dermatologi Malaysia
... investigations may be needed if patients were put on systemic therapy. Examples of oral medications commonly used to treat psoriasis are methotrexate, acitretin and cyclosporine. Injection form of psoriasis treatment includes methotrexate and biologics. Biologics are bioengineered protein designed t ...
... investigations may be needed if patients were put on systemic therapy. Examples of oral medications commonly used to treat psoriasis are methotrexate, acitretin and cyclosporine. Injection form of psoriasis treatment includes methotrexate and biologics. Biologics are bioengineered protein designed t ...
Management of Fibromyalgia Syndrome
... from 6 to 17 sessions. Educational groups improved on 1 or more outcomes including pain, sleep, fatigue, selfefficacy, quality of life, and the 6-minute walk. Changes in the treated groups were maintained for 3 to 12 months. A single multidisciplinary education program, conducted over 11⁄2 days with ...
... from 6 to 17 sessions. Educational groups improved on 1 or more outcomes including pain, sleep, fatigue, selfefficacy, quality of life, and the 6-minute walk. Changes in the treated groups were maintained for 3 to 12 months. A single multidisciplinary education program, conducted over 11⁄2 days with ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.